In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
StartupHub.ai
AION Labs, a pioneering innovation lab dedicated to utilizing AI technologies and computational science for tackling therapeutic challenges, and BioMed X, an independent German research institute, have announced their 2023 global call for applications. They are seeking talented technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
PR Newswire
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
BioSpace
Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS) seeks global research talent for new startup focused on: “AI Powered Discovery to Enable Molecular Glue Therapies.”
Visit: AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AION Labs, In Continued Partnership with BioMed X, Launches First 2023 Global Call for Applications: Developing Molecular Glues
AITHORITY
AION Labs, a first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and German independent research institute BioMed X, announced the launch of its first 2023 global call for applications to identify technological and biomedical scientists and inventors to form a new startup at AION Labs’ headquarters in Rehovot, Israel.
Visit: AION Labs launches second startup focused on AI-enabled antibody design
AION Labs launches second startup focused on AI-enabled antibody design
MobiHealthNews
DenovAI will create an AI-powered platform to discover potential antibodies from scratch, then suggest which ones can be used as effective drugs.
Visit: AION Labs Launches AI Startup for De Novo Antibody Design
AION Labs Launches AI Startup for De Novo Antibody Design
PR Newswire
DenovAI is the second company to be formed by Israel-based alliance of AstraZeneca, Merck, Pfizer, Teva, Israel Biotech Fund and Amazon Web Services (AWS), powered by BioMed X.
Visit: Israel lab backed by pharma giants mints startup for computer-designed antibodies
Israel lab backed by pharma giants mints startup for computer-designed antibodies
Times of Israel
AION Labs, a consortium formed by Pfizer, Merck, AstraZeneca, Teva and others, sets up company to build a computational platform to design live-saving antibodies from scratch
Visit: New Israeli company aims to design life-saving proteins from scratch
New Israeli company aims to design life-saving proteins from scratch
The Jerusalem Post
DenovAI is approved by the Israel Innovation Authority and will receive a $2 million grant from AION Labs and its investment partners Pfizer, AstraZeneca, Merck, Teva and Israel Biotech Fund.